Zealand Pharma major shareholder announcement: Van Herk Investments
2022年10月11日 - 12:12AM
Company announcement – No. 46 / 2022
Zealand Pharma major shareholder announcement: Van Herk
Investments
Copenhagen, Denmark and Boston, MA, 10 October 2022 –
Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50
78), a Copenhagen-based biotechnology company focused on the
discovery and development of innovative peptide-based medicines,
today announces the receipt of notification dated 10 October 2022
pursuant to Section 38 of the Danish Capital Markets Act from the
following major shareholders:
As from 7 October 2022 Van Herk Investments B.V. (Dutch
registration no. 59055057) holds nominally 7,630,244 shares (each
share carrying one vote) in Zealand Pharma A/S, corresponding to
14,81% of the total share capital and total voting rights Zealand
Pharma A/S.
Van Herk Investments B.V. is 100% owned by Van Herk Investments
THI B.V. which is 100% owned by Van Herk Private Equity Investments
B.V. (Dutch registration no. 58894543, which is ultimately owned
and controlled by Mr. Adrianus van Herk.
Van Herk Management Services B.V. (Dutch registration no.
24377325) controls and exercises the voting rights on behalf of Van
Herk Investments B.V., and accordingly, Van Herk Management
Services B.V controls and exercises the voting rights on nominally
7,630,244 shares (each share carrying one vote), corresponding to
14,81% of the total share capital and total voting rights in
Zealand Pharma A/S.
Van Herk Management Services B.V., is controlled by OGBB A. van
Herk B.V. (Dutch registration no. 24160906), which is controlled by
A. van Herk Holding B.V. (Dutch registration no. 24160780), which
is ultimately controlled by Mr. Adrianus van Herk.
Please see further details in the attached notification
forms.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery and development of peptide-based
medicines. More than 10 drug candidates invented by Zealand have
advanced into clinical development, of which two have reached the
market and three candidates are in late-stage development. In
addition, license collaborations with Boehringer Ingelheim and
AstraZeneca create opportunities for more patients to potentially
benefit from Zealand-invented peptide investigational agents
currently in development.
Zealand was founded in 1998 and is headquartered in Copenhagen,
Denmark, with a presence in the U.S. that includes Boston. For more
information about Zealand’s business and activities, please
visit www.zealandpharma.com.
Contact:
Anna Krassowska, PhD Vice President, Investor Relations &
Corporate Communications Zealand Pharma Email:
ank@zealandpharma.com David Rosen (U.S. Media) Argot
Partners Email:
media@zealandpharma.com
|
- 20221007 FSA - Standardformular english Van Herk Investments BV
sign
- 20221007 FSA - Standardformular english Van Herk Management
Services BV sign
Zealand Pharma AS (NASDAQ:ZEAL)
過去 株価チャート
から 5 2024 まで 6 2024
Zealand Pharma AS (NASDAQ:ZEAL)
過去 株価チャート
から 6 2023 まで 6 2024